ERBB2 and acute lymphoblastic leukemia: Moreover, as Trastuzumab has already been successfully used in clinical ALL trials [6], application to HER2/neu+ ALL patients and/or combined application with Rituximab in CD20+HER2/neu+ double positive patients, in our view, could also directly be evaluated in humans.